한글목차

혈전증 및 지혈 바이오마커 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 51억 7,000만 달러에서 2026년에는 55억 6,000만 달러에 이르고, CAGR 7.6%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 응고 바이오마커의 가용성 제한, 수동 및 반자동 분석기기에 대한 의존도, 심혈관 질환의 유병률 증가, 진단 검사 인프라 확대, 혈전증 및 지혈 장애에 대한 인식 증가 등을 들 수 있습니다.

혈전·지혈 바이오마커 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 73억 7,000만 달러에 이르고, CAGR은 7.3%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 전자동 분석기 기술 발전, POCT(Point of Care) 응고장치 도입 확대, 개인 맞춤형 의료에 대한 투자 증가, 의약품 및 진단 연구 확대, 질병 조기 발견을 위한 신규 바이오마커 개발 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 첨단 응고 분석기 도입 확대, 현장 검사 솔루션 수요 증가, 심혈관 질환 조기 발견에 대한 관심 증가, 진단 시약 및 면역 측정 키트 확대, 개인 맞춤형 의료에서 바이오마커 검사의 통합 등을 들 수 있습니다.

정밀하고 표적화된 치료법에 대한 수요 증가는 향후 혈전증 및 지혈 바이오마커 시장의 성장을 가속할 것으로 예측됩니다. 정밀 표적 치료는 환자의 질환의 특정 분자 및 유전적 특징에 초점을 맞춘 첨단 치료법으로, 치료 효과를 높이고 원치 않는 부작용을 줄이는 것을 목표로 합니다. 유전적, 분자적 질병 돌연변이에 대한 지식이 확대되면서 임상 결과를 개선하고 부작용을 최소화하는 맞춤형 치료 전략이 가능해졌고, 이러한 치료법에 대한 수요가 증가하고 있습니다. 이러한 수요는 특정 바이오마커를 식별할 수 있는 고정밀 진단 도구의 개발을 촉진하고, 응고 장애에 대한 보다 정확한 치료와 환자 예후 개선을 가능하게 함으로써 혈전증 및 지혈 바이오마커 시장을 뒷받침하고 있습니다. 예를 들어, 호주에 본사를 둔 임상시험수탁기관(CRO) 노보텍에 따르면 2024년 3월 기준 2023년 말까지 미국 식품의약국(FDA)이 승인한 217개의 종양 치료제 중 43%가 정밀 종양학 치료제로 분류되며, 그 중 78개는 데옥시리보핵산(DNA) 또는 차세대 염기서열 분석(NGS)으로 검출 가능한 바이오마커를 포함하고 있습니다.(NGS)로 검출할 수 있는 바이오마커를 내장하고 있었습니다. 따라서 정밀하고 표적화된 치료법에 대한 수요가 증가하면서 혈전증 및 지혈 바이오마커 시장의 성장을 주도하고 있습니다.

혈전 및 지혈 바이오마커 시장에서 사업을 전개하는 주요 기업들은 검사실 워크플로우를 효율화하고 검사 정확도를 높이는 자동화 통합 등 첨단 솔루션 개발에 주력하고 있습니다. 임상검사실의 자동화 통합은 최소한의 수작업으로 검사 프로세스를 수행하는 연결된 자동화 시스템, 장비, 로봇 기술을 도입하는 것을 말합니다. 예를 들어, 2024년 4월 독일 의료 기술 기업 지멘스 헬스케어는 일본 의료 기술 기업 시스멕스와 공동으로 검사실용 지혈 검사 솔루션 통합 포트폴리오를 발표했습니다. 이 포트폴리오에는 출혈 및 응고 장애의 진단 검사를 지원하기 위해 설계된 다양한 기기와 분석 키트가 포함되어 있으며, 자동화된 반사 검사를 통한 동적 검체 라우팅이 가능합니다. 이러한 기능은 추가 인력 없이도 검사 소요 시간을 단축하고 검사 처리 능력을 향상시키는 데 도움이 됩니다. 또한 자동화는 중앙 집중식 관리 및 실시간 모니터링을 지원하고, 지능형 워크플로우 관리, 통합 품질 관리 및 최적화된 자원 활용을 촉진합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Thrombosis and hemostasis biomarkers are biological indicators that offer insights into blood clot formation and the mechanisms that regulate bleeding. These biomarkers assist in assessing the balance between coagulation and clot breakdown, making them essential for evaluating vascular health and diagnosing coagulation-related disorders.

The main products associated with thrombosis and hemostasis biomarkers include reagents and consumables, as well as analyzers. Reagents and consumables consist of critical chemical substances and disposable laboratory materials such as assay kits, buffers, calibrators, and control solutions that are used to detect, measure, and analyze biomarkers related to clotting and bleeding conditions. These biomarkers are assessed using various tests, including D-dimer, antithrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin time (PT), activated partial thromboplastin time (APTT), and others. They are applied across multiple clinical areas such as cardiovascular diseases, neurological disorders, oncology, pregnancy-related conditions, and orthopedic procedures, and are utilized by end users including hospitals, diagnostic laboratories, pharmaceutical companies, academic institutions, and home healthcare settings.

Tariffs have affected the thrombosis and hemostasis biomarkers market by increasing the cost of imported analyzers, reagents, and calibration materials. Segments such as fully automated coagulation analyzers and specialized immunoassay kits are most impacted, particularly in regions like Asia-Pacific and Europe where imports constitute a significant portion of supply. The tariffs have led to higher production costs and slowed expansion in some regions. Positively, tariffs are driving local manufacturing, innovation in reagent formulations, and investment in domestic diagnostic capabilities.

The thrombosis and hemostasis biomarkers market research report is one of a series of new reports from The Business Research Company that provides thrombosis and hemostasis biomarkers market statistics, including thrombosis and hemostasis biomarkers industry global market size, regional shares, competitors with a thrombosis and hemostasis biomarkers market share, detailed thrombosis and hemostasis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the thrombosis and hemostasis biomarkers industry. This thrombosis and hemostasis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $5.17 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of coagulation biomarkers, reliance on manual and semi-automated analyzers, increasing prevalence of cardiovascular disorders, growing diagnostic laboratory infrastructure, rising awareness of thrombosis and hemostasis disorders.

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to technological advancements in fully automated analyzers, increasing adoption of poct coagulation devices, rising investment in personalized medicine, expansion of pharmaceutical and diagnostic research, development of novel biomarkers for early disease detection. Major trends in the forecast period include growing adoption of advanced coagulation analyzers, rising demand for point-of-care testing solutions, increased focus on early detection of cardiovascular disorders, expansion of diagnostic reagents and immunoassay kits, integration of biomarker testing in personalized medicine.

The growing demand for precise and targeted therapies is expected to propel the growth of the thrombosis and hemostasis biomarkers market going forward. Precise and targeted therapies involve advanced treatment approaches that focus on the specific molecular and genetic features of a patient's disease, with the goal of improving treatment effectiveness while reducing unwanted side effects. The demand for such therapies is increasing due to expanding knowledge of genetic and molecular disease variations, which enables more personalized treatment strategies that enhance clinical outcomes and minimize adverse reactions. This demand supports the thrombosis and hemostasis biomarkers market by driving the development of highly accurate diagnostic tools capable of identifying specific biomarkers, allowing for better-targeted therapies for clotting disorders and improved patient outcomes. For instance, in March 2024, according to Novotech, an Australia-based contract research organization (CRO), among the 217 oncology therapies approved by the U.S. Food and Drug Administration by the end of 2023, 43% were categorized as precision oncology treatments, with 78 incorporating biomarkers detectable through deoxyribonucleic acid (DNA) or next-generation sequencing (NGS). Therefore, the growing demand for precise and targeted therapies is driving the growth of the thrombosis and hemostasis biomarkers market.

Major companies operating in the thrombosis and hemostasis biomarkers market are concentrating on developing advanced solutions such as automation integration to streamline laboratory workflows and enhance testing accuracy. Automation integration in clinical laboratories refers to the implementation of connected automated systems, instruments, and robotic technologies that carry out laboratory testing processes with minimal manual involvement. For example, in April 2024, Siemens Healthcare, a Germany-based medical technology company, in collaboration with Sysmex Corporation, a Japan-based medical technology company, launched a combined portfolio of hemostasis testing solutions for laboratories. This portfolio includes a broad range of established instruments and assay kits designed to support diagnostic testing for bleeding and clotting disorders, enabling dynamic sample routing with automated reflex testing. These capabilities help reduce turnaround times and increase testing throughput without requiring additional staff. Furthermore, automation supports centralized control and real-time monitoring, facilitating intelligent workflow management, integrated quality control, and optimized resource utilization.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This acquisition aims to strengthen Procuritas' presence in the rapidly growing thrombosis and hemostasis diagnostics market by leveraging Precision BioLogic's FDA-cleared reagents, plasma-based products, and strong research and development capabilities, along with Affinity Biologicals' custom assay services, to capitalize on global healthcare trends. Precision BioLogic (PBI) is a Canada-based provider of diagnostic products for blood coagulation disorders, while Affinity Biologicals is a Canada-based manufacturer of products used in thrombosis and hemostasis research and diagnostics.

Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company (BD), Mayo Clinic Laboratories, bioMerieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombosis and hemostasis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombosis And Hemostasis Biomarkers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses thrombosis and hemostasis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombosis and hemostasis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thrombosis and hemostasis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Reagents And Consumables; Analyzers
• 2) By Test Type: D-Dimer; Anti-Thrombin III; Plasminogen; Soluble Fibrin; Factor VIII; Post-Thrombin (PT); Activated Partial Thromboplastin Time (APTT) Test; Other Test Types
• 3) By Application: Cardiovascular Disorders; Neurological Disorders; Oncology; Pregnancy-Related Disorders; Orthopedic Procedures
• 4) By End User: Hospitals; Diagnostics Laboratories; Pharmaceutical Companies; Academic Institutions; Home Healthcare Settings
• Subsegments:
• 1) By Reagents And Consumables: Coagulation Reagents; Control And Calibration Materials; Immunoassay Kits
• 2) By Analyzers: Fully Automated Coagulation Analyzers; Semi-Automated Coagulation Analyzers; Point-Of-Care Coagulation Devices
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Becton Dickinson and Company (BD); Mayo Clinic Laboratories; bioMerieux S.A.; Beckman Coulter Inc.; QuidelOrtho Corporation; Bio-Rad Laboratories Inc.; ARUP Laboratories; HORIBA Ltd.; Werfen S.A.; Pathkind Diagnostics Pvt. Ltd.; Diagnostica Stago; Agilus Diagnostics; Helena Laboratories Corporations; Cleveland Clinic Laboratories; Diazyme Laboratories Inc.; Biomedica Diagnostics Inc.; Atlas Medical GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Thrombosis And Hemostasis Biomarkers Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Thrombosis And Hemostasis Biomarkers Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Thrombosis And Hemostasis Biomarkers Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Thrombosis And Hemostasis Biomarkers Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Growing Adoption Of Advanced Coagulation Analyzers
  • 4.2.2 Rising Demand For Point-Of-Care Testing Solutions
  • 4.2.3 Increased Focus On Early Detection Of Cardiovascular Disorders
  • 4.2.4 Expansion Of Diagnostic Reagents And Immunoassay Kits
  • 4.2.5 Integration Of Biomarker Testing In Personalized Medicine

5. Thrombosis And Hemostasis Biomarkers Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostics Laboratories
• 5.3 Pharmaceutical Companies
• 5.4 Academic Institutions
• 5.5 Home Healthcare Settings

6. Thrombosis And Hemostasis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Thrombosis And Hemostasis Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Thrombosis And Hemostasis Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Thrombosis And Hemostasis Biomarkers Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Thrombosis And Hemostasis Biomarkers Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Thrombosis And Hemostasis Biomarkers Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Thrombosis And Hemostasis Biomarkers Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Thrombosis And Hemostasis Biomarkers Market Segmentation

• 9.1. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Reagents And Consumables, Analyzers
• 9.2. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin, Factor VIII, Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, Other Test Types
• 9.3. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiovascular Disorders, Neurological Disorders, Oncology, Pregnancy-Related Disorders, Orthopedic Procedures
• 9.4. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Diagnostics Laboratories, Pharmaceutical Companies, Academic Institutions, Home Healthcare Settings
• 9.5. Global Thrombosis And Hemostasis Biomarkers Market, Sub-Segmentation Of Reagents And Consumables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Coagulation Reagents, Control And Calibration Materials, Immunoassay Kits
• 9.6. Global Thrombosis And Hemostasis Biomarkers Market, Sub-Segmentation Of Analyzers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fully Automated Coagulation Analyzers, Semi-Automated Coagulation Analyzers, Point-Of-Care Coagulation Devices

10. Thrombosis And Hemostasis Biomarkers Market Regional And Country Analysis

• 10.1. Global Thrombosis And Hemostasis Biomarkers Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Thrombosis And Hemostasis Biomarkers Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market

• 11.1. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Thrombosis And Hemostasis Biomarkers Market

• 12.1. China Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Thrombosis And Hemostasis Biomarkers Market

• 13.1. India Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Thrombosis And Hemostasis Biomarkers Market

• 14.1. Japan Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Thrombosis And Hemostasis Biomarkers Market

• 15.1. Australia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Thrombosis And Hemostasis Biomarkers Market

• 16.1. Indonesia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Thrombosis And Hemostasis Biomarkers Market

• 17.1. South Korea Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Thrombosis And Hemostasis Biomarkers Market

• 18.1. Taiwan Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Thrombosis And Hemostasis Biomarkers Market

• 19.1. South East Asia Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Thrombosis And Hemostasis Biomarkers Market

• 20.1. Western Europe Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Thrombosis And Hemostasis Biomarkers Market

• 21.1. UK Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Thrombosis And Hemostasis Biomarkers Market

• 22.1. Germany Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Thrombosis And Hemostasis Biomarkers Market

• 23.1. France Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Thrombosis And Hemostasis Biomarkers Market

• 24.1. Italy Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Thrombosis And Hemostasis Biomarkers Market

• 25.1. Spain Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Thrombosis And Hemostasis Biomarkers Market

• 26.1. Eastern Europe Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Thrombosis And Hemostasis Biomarkers Market

• 27.1. Russia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Thrombosis And Hemostasis Biomarkers Market

• 28.1. North America Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Thrombosis And Hemostasis Biomarkers Market

• 29.1. USA Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Thrombosis And Hemostasis Biomarkers Market

• 30.1. Canada Thrombosis And Hemostasis Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Thrombosis And Hemostasis Biomarkers Market

• 31.1. South America Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Thrombosis And Hemostasis Biomarkers Market

• 32.1. Brazil Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Thrombosis And Hemostasis Biomarkers Market

• 33.1. Middle East Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Thrombosis And Hemostasis Biomarkers Market

• 34.1. Africa Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Segmentation By Test Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Thrombosis And Hemostasis Biomarkers Market Regulatory and Investment Landscape

36. Thrombosis And Hemostasis Biomarkers Market Competitive Landscape And Company Profiles

• 36.1. Thrombosis And Hemostasis Biomarkers Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Thrombosis And Hemostasis Biomarkers Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Thrombosis And Hemostasis Biomarkers Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Becton Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis

37. Thrombosis And Hemostasis Biomarkers Market Other Major And Innovative Companies

• Mayo Clinic Laboratories, bioMerieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc.

38. Global Thrombosis And Hemostasis Biomarkers Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Thrombosis And Hemostasis Biomarkers Market

40. Thrombosis And Hemostasis Biomarkers Market High Potential Countries, Segments and Strategies

• 40.1 Thrombosis And Hemostasis Biomarkers Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Thrombosis And Hemostasis Biomarkers Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Thrombosis And Hemostasis Biomarkers Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer